The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options
1University of Paris-Cité, Hôpital Beaujon, Service d'hépatologie AP-HP & INSERM UMR1149, Clichy, France. Electronic address: tarik.asselah@aphp.fr.
Abstract
HDV use the cell enzymes for its own replication, and the HBsAg as an envelope. There is an urgent need to develop new drugs for chronic hepatitis D (CHD). Pegylated interferon alpha (PEG-IFNα) (direct-antiviral and immune modulator) has been used and recommended by scientific guidelines, although not approved, with moderate efficacy and poor tolerability. There are several drugs in development which target the host: bulevirtide (BLV), lonafarnib (LNF), nucleic acid polymer, and others.